Clinical Study
Effects of a Long-Acting Formulation of Octreotide on Patients with Portal Hypertension
Table 1
Patient characteristics.
| | TIPS | OCT-LAR | |
| Patients (M/F) | 9/3 | 8/4 | 0.65 | Age (years) | 49.6 ± 8.7 | 50.8 ± 9.8 | 0.76 | Child scores | 8.1 ± 0.5 | 8.0 ± 0.6 | 0.72 | Chronic active hepatitis/alcoholic cirrhosis | 9/3 | 9/3 | 1.0 | Follow-up time (d) | 79.2 ± 19.9 | 82.1 ± 16.8 | 0.69 |
|
|